Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2021 | Dato-DXd: a new ADC on the block

Sara Tolaney, MD, Dana Farber Cancer Institute, Boston, MA, discusses the preliminary results from an ongoing Phase I study evaluating datopotamab deruxtecan (Dato-DXd), a Trop2-directed antibody-drug conjugate (ADC) for patients with triple-negative (TNBC) breast cancer. This novel agent was associated with a response rate of over 40% in this heavily pre-treated metastatic TNBC population, and had a tolerable toxicity profile. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

Disclosures

Sara Tolaney, MD, has received institutional research funds and honoraria from AstraZeneca, Eli Lilly, Merck, Nektar, Novartis, Pfizer, Genenrach/Roche, Immunomedics/Gi lead, Exelixis and Brsitol-Myers Squibb.